A Framework That Explains What Modern Classification Misses
Modern clinical staging of HS — the Hurley classification — describes the structural extent of the disease at the time of evaluation: the number of affected areas, the presence of sinus tracts, the degree of scarring. It is a useful tool for communicating severity and for making decisions about surgical intervention. What it does not provide is an account of the process that produced those structural findings — the internal trajectory along which the disease moved to reach its current state.
The Ayurvedic model of disease progression offers precisely this: not a static description of what is present, but a dynamic account of how the disease moved from initial imbalance to current expression. This account has direct practical value — not because it replaces modern clinical assessment, but because it provides the conceptual framework for understanding why the disease is at the stage it is, what drove it there, and what reversing it requires at this particular depth of involvement.
"HS is not a skin problem. It is a systemic inflammatory condition expressing through the skin."
The Six Stages of Disease Progression — Applied to HS
Classical Ayurvedic pathogenesis describes six sequential stages through which disease progresses from initial imbalance to full structural expression. In the context of HS, these stages map with considerable precision onto the clinical trajectory that patients and clinicians recognise — and they illuminate aspects of that trajectory that the Hurley classification does not capture.
Stage One — Accumulation
Stage I The process begins with the accumulation of Dosha — the regulatory principles whose balance governs systemic function. In HS, the primary accumulation is Pitta — the metabolic and transformative principle — most commonly in the digestive system. Poor dietary choices, irregular eating patterns, cumulative stress, and early gut microbiome disruption create a state in which the metabolic fire (Agni) begins to produce incompletely processed residue rather than clean nutritive output. This is the Ama generation phase — the earliest stage at which the pathological trajectory of HS begins, often years before any skin manifestation appears.
At this stage, the person may experience subtle signs: digestive discomfort, fatigue, skin that seems reactive, occasional small lumps that resolve spontaneously. Nothing that demands medical attention. The internal process, however, is already in motion — and the ease of interruption at this stage is dramatically greater than at any subsequent stage.
Stage Two — Aggravation
Stage II The accumulated Dosha becomes aggravated — quantitatively increased beyond its normal range and qualitatively altered in ways that impair its regulatory function. In HS terms, this corresponds to the progressive worsening of gut dysfunction, the deepening of hormonal dysregulation, and the elevation of the systemic inflammatory baseline above the threshold at which the body's own regulatory responses can contain it. The person may begin to notice more consistent skin reactivity — occasional painful nodules, slightly longer recovery times.
The aggravation stage is still primarily functional. The structural changes that characterise later disease have not yet occurred. This is still a stage at which correction is relatively direct — addressing the accumulation and aggravation at the digestive and systemic level without needing to engage with structural consequences.
Stage Three — Spread
Stage III The aggravated Dosha leaves its primary location — the gastrointestinal tract — and begins to move through the circulatory and regulatory channels of the body. In HS, this corresponds to the systemic spread of inflammatory material and hormonal disruption beyond their sites of origin. The inflammation that began as a gut-localised dysfunction is now circulating — reaching the follicular tissue of the susceptible anatomical zones, disrupting immune regulation at a systemic level, affecting metabolic function in organs distant from the gut.
The spread stage is the beginning of what patients experience as escalation: more frequent episodes, new locations becoming involved, symptoms that extend beyond the skin to include fatigue, mood disruption, and systemic inflammatory burden. The disease is no longer localised to a gut dysfunction that happens to produce skin consequences — it has become a genuinely systemic process.
Stage Four — Localisation
Stage IV The spread Dosha finds and settles in vulnerable tissues — areas of pre-existing structural susceptibility where the regulatory channels are compromised or where specific tissue characteristics make the inflammatory material particularly damaging. In HS, localisation corresponds to the settling of the systemic inflammation in the follicular-rich zones where HS characteristically expresses: axillary, inguinal, inframammary, perianal. The disease is no longer diffuse — it has found its target tissue and is beginning to produce consistent, location-specific expression.
This is the point at which HS becomes clinically recognisable as HS — the recurring painful lesions in consistent locations that characterise the early-to-mid stage disease experience. The localisation is not random: it reflects the interaction between the systemic inflammatory load (which could, in principle, express anywhere) and the specific tissue characteristics of the locations where HS appears (which create the specific susceptibility that HS exploits).
Stage Five — Manifestation
Stage V The disease is now fully expressed in its target tissue. Lesions are forming, recurring, and beginning to produce structural changes in the affected areas. This corresponds to what most patients experience as established HS — the period during which the condition is typically diagnosed, treatment is sought, and the cycle of partial improvement and relapse begins. The disease at this stage has both a functional dimension (the ongoing internal drivers) and a structural dimension (the beginning of follicular architecture disruption, early fibrosis, and the tissue changes that make the local environment increasingly vulnerable to subsequent episodes).
Stage Six — Structural Differentiation
Stage VI The final stage of Ayurvedic pathogenesis involves structural differentiation — the development of distinct, secondary pathological structures that are themselves generators of further disease activity. In HS, this is the development of sinus tracts, chronic fistulae, significant fibrosis, and the structural sequelae of years of recurrent inflammation. These structures are not simply the consequence of the disease — they become active contributors to its maintenance. Sinus tracts create persistent low-grade inflammatory environments. Fibrosed tissue has impaired healing capacity. The structural changes of Stage VI have their own contribution to disease chronicity that must be addressed as part of any comprehensive correction approach.
The significance of this six-stage model for treatment planning is not academic. It directly determines what correction requires at any given point in the disease trajectory. A patient at Stages 1–2 requires primarily functional correction — addressing the accumulation and aggravation of inflammatory load before it has spread and localised. A patient at Stages 3–4 requires both functional correction and channel-clearing measures that address the spread of inflammatory material through the body's regulatory channels. A patient at Stages 5–6 requires all of the above, plus active tissue restoration and management of the structural consequences that are now themselves contributing to the disease. The EPOH approach is built on this stage-dependent correction logic — not because the Ayurvedic model is applied dogmatically, but because the sequencing it implies reflects the actual clinical requirements at each depth of disease involvement.
What "Collapse" Means — The Loss of Functional Reserve
The term "progressive collapse" in the context of HS refers not to the appearance of new lesions, but to the progressive erosion of the body's functional reserve — its capacity to regulate, buffer, and contain the disease process. At Stages 1–2, this reserve is substantially intact. The body can, with appropriate support, begin to correct the imbalance before it has caused lasting structural change. At Stage 6, the reserve has been significantly depleted: the gut's regulatory capacity has been compromised by years of dysfunction and antibiotic exposure; the immune system's regulatory functions have been exhausted by sustained activation; the tissue's healing capacity has been impaired by cumulative structural damage.
This progressive collapse of functional reserve is why HS that has been established for fifteen years does not respond to the same approach that would be appropriate for HS of two years' duration. The required depth of intervention, the appropriate timeline of correction, and the realistic scope of reversal all differ — because the functional reserve available to support correction has been progressively diminished by the disease process itself.
Why Stage Determines Correction Scope
The practical implication of this framework is that treatment cannot be standardised across disease stages. A patient at Stage 2–3 of the Ayurvedic trajectory requires primarily functional correction — restoring gut integrity, reducing the systemic inflammatory load, rebalancing the hormonal environment. Given sufficient time and appropriate support, this correction can produce near-complete reversal because the structural consequences are minimal and the tissue's healing capacity is largely intact.
A patient at Stage 5–6 requires all of this, plus active tissue restoration work that addresses the structural changes in affected areas — the fibrosis, the disrupted follicular architecture, the impaired local healing capacity. The functional correction is still necessary — without it, the structural restoration has no stable internal environment to consolidate within. But functional correction alone is insufficient when the structural consequences of years of active disease are themselves contributing to recurrence.
This is not a reason for discouragement. Stage 5–6 HS is correctable. But it requires more, and it takes longer — because the depth of the disease at that stage reflects a longer and more extensive internal trajectory than the Hurley Stage III classification alone captures.
"If it keeps coming back, it means the root cause has not been addressed."
The Value of This Framework for Patients
For patients, the value of the Ayurvedic progressive disease framework is that it makes the disease trajectory legible in a way that standard clinical staging does not. It explains not just where the disease is, but how it got there — the sequence of internal events that moved it from an initial functional imbalance to its current state of structural expression. This explanation is not merely intellectually satisfying. It informs realistic expectations about what correction can accomplish at the current stage, what it will require, and how long it will take.
It also makes clear why earlier correction is meaningfully better — not in a way designed to generate anxiety about having delayed treatment, but in a factual way that reflects the actual relationship between disease stage, functional reserve, and correction complexity. The same correction that takes four months at Stage 3 may take twelve months at Stage 5. Not because the approach is less effective, but because the depth of what it is correcting is genuinely greater.